{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:11:26Z","timestamp":1780351886229,"version":"3.54.1"},"reference-count":155,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14391","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T10:39:22Z","timestamp":1712659162000},"source":"Crossref","is-referenced-by-count":6,"title":["The numerous facets of 1q21<sup>+<\/sup> in multiple myeloma: Pathogenesis, clinicopathological features, prognosis and clinical progress (Review)"],"prefix":"10.3892","volume":"27","author":[{"given":"Na","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanzhi","family":"Xie","sequence":"additional","affiliation":[{"name":"Sanofi China Investment Co., Ltd. Shanghai Branch, Shanghai 200000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"key20240516111813_b1-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"key20240516111813_b2-ol-27-6-14391","first-page":"377","article-title":"Modern imaging techniques for monitoring patients with multiple myeloma","volume":"95","author":"Pop","year":"2022","journal-title":"Med Pharm Rep"},{"key":"key20240516111813_b3-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: A global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"key20240516111813_b4-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 Update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"key20240516111813_b5-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/ijc.33762","article-title":"Epidemiology, genetics and treatment of multiple myeloma and precursor diseases","volume":"149","author":"Hemminki","year":"2021","journal-title":"Int J Cancer"},{"key":"key20240516111813_b6-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma-opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"key20240516111813_b7-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"key20240516111813_b8-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20240516111813_b9-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20240516111813_b10-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"key20240516111813_b11-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1200\/EDBK_320105","article-title":"How to treat high-risk myeloma at diagnosis and relapse","volume":"41","author":"Caro","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20240516111813_b12-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome instability in multiple myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"key":"key20240516111813_b13-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"key20240516111813_b14-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"key20240516111813_b15-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"key20240516111813_b16-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/cells10061360","article-title":"Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets","volume":"10","author":"Burroughs Garc\u00eca","year":"2021","journal-title":"Cells"},{"key":"key20240516111813_b17-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17474086.2021.1983427","article-title":"Chromosomal 1q21 abnormalities in multiple myeloma: A review of translational, clinical research, and therapeutic strategies","volume":"14","author":"Bisht","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"key20240516111813_b18-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.26639","article-title":"Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications","volume":"97","author":"Kastritis","year":"2022","journal-title":"Am J Hematol"},{"key":"key20240516111813_b19-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1634\/theoncologist.2019-0132","article-title":"1q21 gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: A multicenter study in China","volume":"24","author":"Li","year":"2019","journal-title":"Oncologist"},{"key":"key20240516111813_b20-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"S5593","DOI":"10.1182\/blood-2019-130092","article-title":"Significance of modified risk stratification msmart 3.0 and autologous stem cell transplantation for patients with newly diagnosed multiple myeloma","volume":"134","author":"Garifullin","year":"2019","journal-title":"Blood"},{"key":"key20240516111813_b21-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"key":"key20240516111813_b22-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20240516111813_b23-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"752.e1","DOI":"10.1016\/j.jtct.2022.07.028","article-title":"Lenalidomide-based maintenance after autologous hematopoietic stem cell transplantation for patients with high-risk multiple myeloma","volume":"28","author":"Pasvolsky","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"key20240516111813_b24-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1080\/10428194.2022.2123229","article-title":"Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA\/Spanish myeloma group (GEM)","volume":"63","author":"Villalba","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"key20240516111813_b25-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1007\/s00277-022-04978-6","article-title":"Adverse outcome associated with daratumumab-based treatments in relapsed\/refractory multiple myeloma patients with amplification of chromosome arm 1q21: A single-center retrospective experience","volume":"101","author":"Barbieri","year":"2022","journal-title":"Ann Hematol"},{"key":"key20240516111813_b26-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.7150\/jca.40711","article-title":"Prognostic value and efficacy evaluation of novel drugs for multiple myeloma patients with 1q21 amplification (Amp1q21) only: A systematic review of randomized controlled trials","volume":"11","author":"Chen","year":"2020","journal-title":"J Cancer"},{"key":"key20240516111813_b27-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"e24375","DOI":"10.1002\/jcla.24375","article-title":"Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis","volume":"36","author":"Wang","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"key20240516111813_b28-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"938392","DOI":"10.3389\/fonc.2022.938392","article-title":"The independent adverse prognostic significance of 1q21 gain\/amplification in newly diagnosed multiple myeloma patients","volume":"12","author":"You","year":"2022","journal-title":"Front Oncol"},{"key":"key20240516111813_b29-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20240516111813_b30-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"key20240516111813_b31-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/gcc.20109","article-title":"Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q","volume":"42","author":"Sawyer","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"key20240516111813_b32-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"key20240516111813_b33-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ijlh.12882","article-title":"Recent advances in cytogenetic characterization of multiple myeloma","volume":"41","author":"Saxe","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"key20240516111813_b34-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2013-12-546077","article-title":"Jumping translocations of 1q12 in multiple myeloma: A novel mechanism for deletion of 17p in cytogenetically defined high-risk disease","volume":"123","author":"Sawyer","year":"2014","journal-title":"Blood"},{"key":"key20240516111813_b35-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1182\/blood.V91.5.1732","article-title":"Jumping translocations of chromosome 1q in multiple myeloma: Evidence for a mechanism involving decondensation of pericentromeric heterochromatin","volume":"91","author":"Sawyer","year":"1998","journal-title":"Blood"},{"key":"key20240516111813_b36-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-019-0226-4","article-title":"An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q syndrome","volume":"9","author":"Sawyer","year":"2019","journal-title":"Blood Cancer J"},{"key":"key20240516111813_b37-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"key20240516111813_b38-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"key":"key20240516111813_b39-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"key":"key20240516111813_b40-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-20-4366","article-title":"Functional impact of genomic complexity on the transcriptome of multiple myeloma","volume":"27","author":"Ziccheddu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20240516111813_b41-ol-27-6-14391","first-page":"546","article-title":"The role of interleukin-6 and interleukin-6\/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma","volume":"11","author":"Barill\u00e9","year":"2000","journal-title":"Eur Cytokine Netw"},{"key":"key20240516111813_b42-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3324\/haematol.2019.221176","article-title":"IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification","volume":"105","author":"Teoh","year":"2020","journal-title":"Haematologica"},{"key":"key20240516111813_b43-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/cbir.2000.0497","article-title":"Role of interleukin-6 in the pathogenesis of multiple myeloma","volume":"24","author":"Gad\u00f3","year":"2000","journal-title":"Cell Biol Int"},{"key":"key20240516111813_b44-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/1759-7714.12633","article-title":"Molecular cross-talk of IL-6 in tumors and new progress in combined therapy","volume":"9","author":"Song","year":"2018","journal-title":"Thorac Cancer"},{"key":"key20240516111813_b45-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0002-9440(10)64278-2","article-title":"Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events","volume":"162","author":"Quintanilla-Martinez","year":"2003","journal-title":"Am J Pathol"},{"key":"key20240516111813_b46-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood.V96.9.3147.h8003147_3147_3153","article-title":"Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma","volume":"96","author":"Treon","year":"2000","journal-title":"Blood"},{"key":"key20240516111813_b47-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am J Pathol"},{"key":"key20240516111813_b48-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4149\/neo_2009_05_404","article-title":"Nuclear topography of the 1q21 genomic region and Mcl-1 protein levels associated with pathophysiology of multiple myeloma","volume":"56","author":"Legartova","year":"2009","journal-title":"Neoplasma"},{"key":"key20240516111813_b49-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"key":"key20240516111813_b50-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"key20240516111813_b51-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","article-title":"Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3","volume":"118","author":"Shaughnessy","year":"2011","journal-title":"Blood"},{"key":"key20240516111813_b52-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell"},{"key":"key20240516111813_b53-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","article-title":"ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma","volume":"32","author":"Marchesini","year":"2017","journal-title":"Cancer Cell"},{"key":"key20240516111813_b54-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1002\/cam4.1596","article-title":"ARNT\/HIF-1\u03b2 links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma","volume":"7","author":"Wu","year":"2018","journal-title":"Cancer Med"},{"key":"key20240516111813_b55-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"3307873","DOI":"10.1155\/2022\/3307873","article-title":"Increased expression of SETDB1 predicts poor prognosis in multiple myeloma","volume":"2022","author":"Xiang","year":"2022","journal-title":"Biomed Res Int"},{"key":"key20240516111813_b56-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1182\/blood-2015-03-632075","article-title":"Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma","volume":"125","author":"Sawyer","year":"2015","journal-title":"Blood"},{"key":"key20240516111813_b57-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3324\/haematol.2019.222133","article-title":"The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation","volume":"105","author":"Chatonnet","year":"2020","journal-title":"Haematologica"},{"key":"key20240516111813_b58-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1182\/blood.2021014391","article-title":"Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma","volume":"139","author":"Trasanidis","year":"2022","journal-title":"Blood"},{"key":"key20240516111813_b59-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3389\/fimmu.2018.00764","article-title":"Complement component C1q: Historical perspective of a functionally versatile, and structurally unusual, serum protein","volume":"9","author":"Reid","year":"2018","journal-title":"Front Immunol"},{"key":"key20240516111813_b60-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.molimm.2014.06.011","article-title":"cC1qR\/CR and gC1qR\/p33: Observations in cancer","volume":"61","author":"Peerschke","year":"2014","journal-title":"Mol Immunol"},{"key":"key20240516111813_b61-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3389\/fimmu.2020.01292","article-title":"Globular C1q receptor (gC1qR\/p32\/HABP1) suppresses the tumor-inhibiting role of C1q and promotes tumor proliferation in 1q21-amplified multiple myeloma","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"key":"key20240516111813_b62-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2177979","DOI":"10.1080\/16078454.2023.2177979","article-title":"Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: Results from a single-center study","volume":"28","author":"Chen","year":"2023","journal-title":"Hematology"},{"key":"key20240516111813_b63-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ajh.26774","article-title":"Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma","volume":"98","author":"Yang","year":"2023","journal-title":"Am J Hematol"},{"key":"key20240516111813_b64-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"key20240516111813_b65-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2141.2006.06481.x","article-title":"Abnormalities of chromosome 1p\/q are highly associated with chromosome 13\/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"136","author":"Wu","year":"2007","journal-title":"Br J Haematol"},{"key":"key20240516111813_b66-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cancergencyto.2006.02.015","article-title":"Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma","volume":"168","author":"Bang","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"key20240516111813_b67-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.bbmt.2016.09.003","article-title":"Outcome of patients with multiple myeloma and CKS1B gene amplification after autologous hematopoietic stem cell transplantation","volume":"22","author":"Bock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20240516111813_b68-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma-a meta-analysis of 2,596 trial patients","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica"},{"key":"key20240516111813_b69-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"S10056","DOI":"10.1182\/blood-2022-159067","article-title":"The independent adverse prognostic significance of 1q21 gain\/amplification in newly diagnosed multiple myeloma patients","volume":"140","author":"You","year":"2022","journal-title":"Blood"},{"key":"key20240516111813_b70-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"key20240516111813_b71-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/ejh.13771","article-title":"Bone metabolism parameters and their relation to cytogenetics in multiple myeloma","volume":"109","author":"Krhovska","year":"2022","journal-title":"Eur J Haematol"},{"key":"key20240516111813_b72-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.09.001","article-title":"The role of biomarkers in the management of bone-homing malignancies","volume":"9","author":"D'Oronzo","year":"2017","journal-title":"J Bone Oncol"},{"key":"key20240516111813_b73-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.clinbiochem.2009.12.018","article-title":"Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma","volume":"43","author":"Kowalska","year":"2010","journal-title":"Clin Biochem"},{"key":"key20240516111813_b74-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","article-title":"Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial","volume":"35","author":"Croft","year":"2021","journal-title":"Leukemia"},{"key":"key20240516111813_b75-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1097\/CM9.0000000000002735","article-title":"Prognostic value of the second revision of the international staging system (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma","volume":"136","author":"Yan","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"key20240516111813_b76-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","article-title":"Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy","volume":"16","author":"Nemec","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20240516111813_b77-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"key":"key20240516111813_b78-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/ejh.12546","article-title":"Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21","volume":"96","author":"Nahi","year":"2016","journal-title":"Eur J Haematol"},{"key":"key20240516111813_b79-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"key20240516111813_b80-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: A meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"key20240516111813_b81-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.clml.2018.12.002","article-title":"Prognostic value of 1q21 gain in multiple myeloma","volume":"19","author":"Chen","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20240516111813_b82-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"key":"key20240516111813_b83-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"key20240516111813_b84-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv"},{"key":"key20240516111813_b85-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"7819","DOI":"10.1002\/cam4.3254","article-title":"Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China","volume":"9","author":"Gao","year":"2020","journal-title":"Cancer Med"},{"key":"key20240516111813_b86-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2013.088211","article-title":"Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value","volume":"99","author":"An","year":"2014","journal-title":"Haematologica"},{"key":"key20240516111813_b87-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/10428194.2019.1700503","article-title":"1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib","volume":"61","author":"Du","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"key20240516111813_b88-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/cncr.34641","article-title":"The prognostic role of 1q21 gain\/amplification in newly diagnosed multiple myeloma: The faster, the worse","volume":"129","author":"Wang","year":"2023","journal-title":"Cancer"},{"key":"key20240516111813_b89-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clml.2022.01.013","article-title":"The importance of FISH signal cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: Is it underestimated?","volume":"22","author":"Gao","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20240516111813_b90-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"938550","DOI":"10.3389\/fonc.2022.938550","article-title":"Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"key20240516111813_b91-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41408-023-00933-4","article-title":"Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions","volume":"13","author":"Schavgoulidze","year":"2023","journal-title":"Blood Cancer J"},{"key":"key20240516111813_b92-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-023-00973-w","article-title":"Outcomes of patients with multiple myeloma and 1q gain\/amplification receiving autologous hematopoietic stem cell transplant: The MD Anderson cancer center experience","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J"},{"key":"key20240516111813_b93-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"key20240516111813_b94-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20240516111813_b95-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas-current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20240516111813_b96-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","article-title":"Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: An update","volume":"12","author":"Bazarbachi","year":"2022","journal-title":"Blood Cancer J"},{"key":"key20240516111813_b97-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"key20240516111813_b98-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.bbmt.2019.12.726","article-title":"Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: Propensity score matched analysis","volume":"26","author":"Varma","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20240516111813_b99-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/blood-2018-08-825349","article-title":"Pros and cons of frontline autologous transplant in multiple myeloma: The debate over timing","volume":"133","author":"Kumar","year":"2019","journal-title":"Blood"},{"key":"key20240516111813_b100-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","article-title":"Multiple myeloma: Role of autologous transplantation","volume":"82","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"key20240516111813_b101-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"key20240516111813_b102-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20240516111813_b103-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"key20240516111813_b104-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"key20240516111813_b105-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"key20240516111813_b106-ol-27-6-14391","first-page":"262","article-title":"Advances on immunomodulatory drugs against multiple myeloma","volume":"37","author":"Wang","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"key20240516111813_b107-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jjco\/hyz083","article-title":"Immunomodulatory drugs in the treatment of multiple myeloma","volume":"49","author":"Abe","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"key20240516111813_b108-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/8466","article-title":"Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity","volume":"5","author":"Parman","year":"1999","journal-title":"Nat Med"},{"key":"key20240516111813_b109-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"key20240516111813_b110-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"key20240516111813_b111-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.2147\/DDDT.S265793","article-title":"Proteasome, a promising therapeutic target for multiple diseases beyond cancer","volume":"14","author":"Cao","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"key20240516111813_b112-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol Rev"},{"key":"key20240516111813_b113-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: Structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semin Oncol"},{"key":"key20240516111813_b114-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20240516111813_b115-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 Years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"key20240516111813_b116-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. food and drug administration approval: Carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20240516111813_b117-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1084683","DOI":"10.3389\/fonc.2022.1084683","article-title":"The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"key20240516111813_b118-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S2152-2650(21)02126-1","article-title":"OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: Analysis from the ENDURANCE ECOG-ACRIN E1A11 trial","volume":"21","author":"Kapoor","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20240516111813_b119-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"20406207221082043","DOI":"10.1177\/20406207221082043","article-title":"The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain","volume":"13","author":"Tang","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"key20240516111813_b120-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the value of lenalidomide maintenance by extended genetic profiling: An analysis of 556 patients in the Myeloma XI trial","volume":"141","author":"Panopoulou","year":"2023","journal-title":"Blood"},{"key":"key20240516111813_b121-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1182\/blood-2020-137060","article-title":"Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the forte trial","volume":"136","author":"D'Agostino","year":"2020","journal-title":"Blood"},{"key":"key20240516111813_b122-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1182\/bloodadvances.2020002711","article-title":"Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma","volume":"4","author":"Misiewicz-Krzeminska","year":"2020","journal-title":"Blood Adv"},{"key":"key20240516111813_b123-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"key20240516111813_b124-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","article-title":"Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"key":"key20240516111813_b125-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20240516111813_b126-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.7150\/ijbs.68148","article-title":"Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies","volume":"18","author":"Wu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"key20240516111813_b127-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"key20240516111813_b128-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"key20240516111813_b129-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"key20240516111813_b130-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","article-title":"Anti CD38 monoclonal antibodies for multiple myeloma treatment","volume":"18","author":"Gozzetti","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"key20240516111813_b131-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"key20240516111813_b132-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"S7278","DOI":"10.1182\/blood-2022-162339","article-title":"Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): Final analysis of griffin among clinically relevant subgroups","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"key":"key20240516111813_b133-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: Adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome","volume":"189","author":"Mohan","year":"2020","journal-title":"Br J Haematol"},{"key":"key20240516111813_b134-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"S7237","DOI":"10.1182\/blood-2022-169533","article-title":"Therapeutic outcomes of relapsed-refractory multiple myeloma patients with 1q21+treated with daratumumab-based regimens: A retrospective analysis","volume":"140","author":"Parrondo","year":"2022","journal-title":"Blood"},{"key":"key20240516111813_b135-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"S1836","DOI":"10.1182\/blood-2022-156309","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients with high-risk newly diagnosed multiple myeloma: Planned interim analysis of the GMMG-concept trial","volume":"140","author":"Weisel","year":"2022","journal-title":"Blood"},{"key":"key20240516111813_b136-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/bjh.17499","article-title":"Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics","volume":"194","author":"Harrison","year":"2021","journal-title":"Br J Haematol"},{"key":"key20240516111813_b137-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/ejh.13835","article-title":"Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis","volume":"109","author":"Spicka","year":"2022","journal-title":"Eur J Haematol"},{"key":"key20240516111813_b138-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3324\/haematol.2022.280660","article-title":"Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed\/refractory multiple myeloma: Subgroup analyses from ICARIA-MM and IKEMA","volume":"107","author":"Martin","year":"2022","journal-title":"Haematologica"},{"key":"key20240516111813_b139-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20240516111813_b140-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/cancers13020279","article-title":"Immune functions of signaling lymphocytic activation molecule family molecules in multiple myeloma","volume":"13","author":"Ishibashi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20240516111813_b141-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"key":"key20240516111813_b142-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): Primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"key":"key20240516111813_b143-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: A phase 2 measurable residual disease-adapted study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol"},{"key":"key20240516111813_b144-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"78896","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkappaBalpha and overcomes acquired proteasome inhibitor resistance in human multiple myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"key":"key20240516111813_b145-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"key20240516111813_b146-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"key20240516111813_b147-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"25529","DOI":"10.18632\/oncotarget.25368","article-title":"Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death","volume":"9","author":"Argueta","year":"2018","journal-title":"Oncotarget"},{"key":"key20240516111813_b148-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12916-022-02305-4","article-title":"Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study","volume":"20","author":"Qiu","year":"2022","journal-title":"BMC Med"},{"key":"key20240516111813_b149-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41416-021-01608-2","article-title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","volume":"126","author":"Gasparetto","year":"2022","journal-title":"Br J Cancer"},{"key":"key20240516111813_b150-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"key20240516111813_b151-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20240516111813_b152-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International myeloma working group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"key20240516111813_b153-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 Update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"key20240516111813_b154-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20240516111813_b155-ol-27-6-14391","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5603\/AHP.2021.0004","article-title":"Clinical implications of cytogenetic and molecular aberrations in multiple myeloma","volume":"52","author":"Goldman-Mazur","year":"2021","journal-title":"Acta Haematol Pol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T08:19:26Z","timestamp":1715847566000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":155,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,9]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14391","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"article-number":"258"}}